Susceptibility of clinical isolates of frequently encountered bacterial species to tigecycline: Results of a multicentre surveillance trial in Germany (G-TEST, 2005) - Susceptibility of bacterial pathogens to tigecycline;Empfindlichkeit klinischer isolate häufig vorkommender bakterienspezies gegenüber tigecyclin: Ergebnisse einer multizentrischen surveillance-studie in Deutschland (G-TEST, 2005)

Chemotherapie Journal

Volumn 17, Issue 5, 2008, Pages 205-226

  Kresken, Michael ^a   Leitner, Eva ^b   Seifert, Harald ^c   Peters, Georg ^d   Von Eiff, Christof ^d  

^a BONN RHEIN SIEG UNIVERSITY OF APPLIED SCIENCES   (Germany)

^b Wyeth Pharma GmbH   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Gram negative organisms; Gram positive organisms; Resistance surveillance; Tigecycline

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; DOXYCYCLINE; ERTAPENEM; GENTAMICIN; IMIPENEM; LINEZOLID; MOXIFLOXACIN; OXACILLIN; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 54249155715     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005;41(Suppl 5):S315-32.
2. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 18th Informational Supplement. Wayne: Clinical and Laboratory Standards Institute, 2008: M100-S18.
3. Dean CR, Visalli MA, Projan SJ, Sum PE, et al. Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1. Antimicrob Agents Chemother 2003;47:972-8.
4. Fluit AC, Florijn A, Verhoef J, Milatovic D. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 2005;49:1636-8.
5. EARSS European Antimicrobial Resistance Surveillance System. EARSS annual report 2005. European Antimicrobial Resistance Surveillance System, Bilthoven, 2008. http://www.rivm.nl/earss/Images/EARSS%202006%20Def_tcm61-44176.pdf
6. Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. Diagn Microbiol Infect Dis 2004;49:201-9.
7. GENARS German Network for Antimicrobial Resistance Surveillance. http://www.genars.de.
8. Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, et al. Tigecycline Evaluation and Surveillance Trial (TEST Program) Group. In vitro activity of tigecycline against 6,792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 2005;52:215-27.
9. Keeney D, Ruzin A, McAleese F, Murphy E, et al. MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli. J Antimicrob Chemother 2008;61:46-53.
10. Kresken M, Hafner D. Drug resistance among clinical isolates of frequently encountered bacterial species in central Europe during 1975-1995. Study Group Bacterial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Infection 1999;27(Suppl 2):S2-8.
11. Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA, Studiengruppe (2006). Resistenzsituation bei klinisch wichtigen Infektionserregern gegenüber Antibiotika in Deutschland und im mitteleuropäischen Raum. Bericht über die Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e. V. aus dem Jahre 2004. Antiinfectives Intelligence, Rheinbach. http://www.p-e-g.org/ag_resistenz/PEG-Resistenzstudie%202004.pdf
12. Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA, Studiengruppe. Resistenz bei häufig isolierten Enterobacteriaceae gegenüber Breitspektrum-Antibiotika. Chemother J 2007;15:179-90.
13. Kronvall G, Karlsson I, Walder M, Sorberg M, et al. Epidemiological MIC cut-off values for tigecycline calculated from E-test MIC values using normalized resistance interpretation. J Antimicrob Chemother 2006;57:498-505.
14. Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005;56:611-4.
15. McAleese F, Petersen P, Ruzin A, Dunman PM, et al. A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline. Antimicrob Agents Chemother 2005;49:1865-71.
16. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother 2003;47:400-4.
17. Normenausschuss Medizin (NaMed) im DIN Deutsches Institut für Normung e.V. Empfindlichkeitsprüfung von Krankheitserregern gegen Chemotherapeutika (DIN 58940). In: DIN Deutsches Institut für Normung e.V. (editors). DIN-Taschenbuch 222, Medizinische Mikrobiologie, Diagnostische Verfahren. Berlin, Wien, Zürich: Beuth Verlag, 2004:243-442.
18. Pankey GA. Tigecycline. J Antimicrob Chemother 2005;56:470-80.
19. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999;43:738-44.
20. Reinert RR, Al-Laham A, Lemperle M, Tenholte C, et al. Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002;49:61-8.
21. Ruzin A, Keeney D, Bradford PA. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. Antimicrob Agents Chemother 2005;49:791-3.
22. Ruzin A, Visalli MA, Keeney D, Bradford PA. Influence of transcriptional activator RamA on expression of multidrug efflux pump AcrAB and tigecycline susceptibility in Klebsiella pneumoniae. Antimicrob Agents Chemother 2005;49:1017-22.
23. Souli M, Kontopidou FV, Koratzanis E, Antoniadou A, et al. In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother 2006;50:3166-9.
24. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Steering Committee. EUCAST technical note on tigecycline. Clin Microbiol Infect 2006;12:1147-9.
25. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) Clinical breakpoints. European Society of Clinical Microbiology and Infectious Diseases. http://www.srga.org/eucastwt/MICTAB/index.html
26. Trautmann M. Tigecyclin - Mikrobiologie, Pharmakokinetik und klinischer Stellenwert bei schweren Infektionen. Chemother J 2007;16:88-96.
27. Visalli MA, Murphy E, Projan Sj, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003;47:665-9.
28. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006;50:3479-84.
29. Werner G, Gfrörer S, Fleige C, Witte W, et al. Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient. J Antimicrob Chemother 2008;61:1182-3.
30. Woodford N, Hill RLR, Livermore DM. In vitro activity of tigecycline against carbapenem-susceptible and -resistant isolates of Klebsiella spp. and Enterobacter spp. J Antimicrob Chemother 2007;59:582-3.
31. Wyeth Pharmaceuticals Inc. Tygacil product insert. Wyeth Pharmaceuticals Inc., Philadelphia, 2005. http://www.fda.gov/cder/foi/label/2005/021821lbl.pdf